Researchers Find Small Increased Risk of Sudden Vision Loss Associated With GLP-1 Medications While the risk is low, Rutgers researchers say patients should be aware of this potential association A medication commonly used to treat Type 2 diabetes and obesity was associated with a slight increase in risk for a rare condition involving reduced blood flow to the optic nerve that can cause sudden vision loss, according to Rutgers researchers
The mice were then treated with either vehicle, exendin 939, or exendin 2029 in 20 L, which were administered on the same paw where the CFA was injected
"The GLP-1 shortage challenges are exacerbated by a lack of accurate, up-to-date, and accessible GLP-1 supply information
Individual responses vary considerably, and some patients continue experiencing specific food cravings despite effective appetite suppression
In most cases, these effects are temporary, and many patients begin to feel more comfortable as their body adapts to the treatment
